{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:20:25Z","timestamp":1787030425027,"version":"build-2736575974"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.3816\/clm.2004.n.028","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:10:23Z","timestamp":1221081023000},"page":"202-204","source":"Crossref","is-referenced-by-count":29,"title":["Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature"],"prefix":"10.3816","volume":"5","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Pieslor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Emmanouilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Theuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2004.n.028_bib1","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non- Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib3","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2004.n.028_bib4","first-page":"232b","article-title":"High-dose therapy can be safely and successfully administered after Zevalin","volume":"20","author":"Gordon","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib6","first-page":"267a","article-title":"90Y ibritumomab tiuxetan (Zevalin\u00ae) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma","volume":"21","author":"Schilder","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib7","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.028_bib8","first-page":"8a","article-title":"Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy","volume":"21","author":"Saleh","year":"2002","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T17:58:49Z","timestamp":1545760729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511700823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S1526965511700823"],"URL":"https:\/\/doi.org\/10.3816\/clm.2004.n.028","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}